Gilead Stock News

Bullish analyst comments about the potential for a Gilead Sciences Inc. ( GILD , Financial) drug may account for the jump in the company's shares to a 52-week high of $73.34 this week. Newly unveiled

Compagnie Lombard Odier SCmA reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.9% during the third quarter, Holdings Channel reports. The firm owned 38,475 shares of the biopharmaceutical companys stock after selling 2,400 shares during the period. Compagnie Lombard Odier SCmAs holdings in Gilead Sciences were worth $2,686,000 as of its most []

Grandfield & Dodd LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 236,254 shares of the biopharmaceutical companys stock after buying an additional 13,290 shares during the quarter. Grandfield & Dodd []

Gilead Sciences (GILD) closed the most recent trading day at $72.31, moving +1.54% from the previous trading session.

Nanoparticles Market Survival Strategies explore Economic Impact in International Industries Manufactures, Growth, Size, Share, Trends, Development Challenges and Opportunities till 2028. The new research on Nanoparticles gives a fundamental data and factually assessed information about the industry worldwide. The exploration

The trading price of Gilead Sciences Inc. (NASDAQ:GILD) floating lower at last check on Wednesday, December 15, trading at $70.38, -0.20% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Livforsakringsbolaget Skandia Omsesidigt reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 101,737 shares of the biopharmaceutical companys stock after selling 2,300 shares during the period. Livforsakringsbolaget Skandia Omsesidigts holdings in Gilead Sciences were worth $7,103,000 as of its most recent SEC []

Brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to post sales of $6.39 billion for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Gilead Sciences earnings, with the lowest sales estimate coming in at $6.22 billion and the highest estimate coming in at $6.69 billion. Gilead Sciences posted sales of []

Key Players covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Other key market players. Key Players covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Other key market players.

SHANGHAI , Dec. 15, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced today that the Ministry of Food and Drug Safety (MFDS) of South Korea accepted its New Drug Application (NDA) for Sacituzumab Govitecan ("SG") for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The MFDS in South Korea previously granted Fast Track Designation and Orphan Drug Designation to SG for the treatment of mTNBC in April 2021. "We''re extremely proud of this acceptance as breast cancer is the leading cause of death from cancer in South Korean women and one of the fastest growing cancers in the world," said Kerry Blanchard , MD, PhD, Chief Executive Officer of Everest Medicines. "Historically, women with metastatic TNBC have had fewer treatment options available and this application acceptance means we are one step closer in making SG available for women with this aggressive cancer in South Korea ." Under the trade name Trodelvy®, the U.S.

Toronto, Ontario–(Newsfile Corp. – December 14, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:… The post Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors first appeared on IT Business Net .

Washington Trust Bank raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 89.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,287 shares of the biopharmaceutical company’s stock after purchasing an additional 3,437 shares during the quarter. Washington Trust Bank’s […]

Toronto, Ontario--(Newsfile Corp. - December 14, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (''Awakn''), a biotechnology company developing and delivering psychedelic th

OLD National Bancorp IN increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,418 shares of the biopharmaceutical companys stock after purchasing an additional 195 shares during the quarter. OLD National []